The ABC newspaper interviewed Eduard Batlle, about his latest work published in the journal Nature, in which he has managed to cure colon cancer in mice by unblocking the immune system to act against the disease.
Link to ABC
TLK protein inhibition activates the innate immune system
These proteins are a potential therapeutic target for enhancing the effect of some cancer treatments.
Inhibition of TLK proteins triggers the Alternative Lengthening of Telomeres pathway, a common process in some of the most aggressive types of cancer, such as glioblastoma.
The study, performed by the Genomic Instability and Cancer Laboratory at IRB Barcelona, has been published in the journal Cell Reports.
Mutations in cancer genomes: foggy with a chance of thunderstorms
The mechanism unveiled triggers a mutation fog, causing hundreds of mutations in each tumor, which spread through the genome of lung, head-and-neck and breast cancers.
Researchers from the Genome Data Science Lab have identified the antiviral APOBEC3A enzyme as the major cause of this new type of hypermutation.
Published in Nature Genetics, the study shows how the mutation fog process generates many oncogenic “cancer driver” mutations, thus accelerating tumour development.
An interview with Clara Morral, Postdoctoral Fellow at IRB Barcelona
Clara Morral is the first author of an article recently published in the scientific journal Cell Stem Cell.
The study identifies that protein synthesis is a key property for the regenerative potential of colon cancer cells.